WAICHUNBIO-NEW：InterimReport202223.pdf

1、CONTENTSPageCorporate Information2Management Discussion and Analysis3 Other Information7 Condensed Consolidated Statement of Profit or Loss14Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income15 Condensed Consolidated Statement of Financial Position16 Condensed Consolid

2、ated Statement of Changes in Equity18 Condensed Consolidated Statement of Cash Flows19 Notes to the Condensed Consolidated Financial Statements20 Wai Chun Bio-Technology Limited2CORPORATE INFORMATIONAs at 28 February 2023BOARD OF DIRECTORSExecutive DirectorChan Cheuk HoIndependent Non-Executive Dire

3、ctorsHong TingWan BoHung Hoi Ming RaymondAUTHORISED REPRESENTATIVESChan Cheuk HoFenn DavidCOMPANY SECRETARYFenn DavidAUDIT COMMITTEEHong Ting(Chairman)Wan BoHung Hoi Ming RaymondREMUNERATION COMMITTEEHong Ting(Chairman)Chan Cheuk HoWan BoHung Hoi Ming RaymondNOMINATION COMMITTEEWan Bo(Chairman)Chan

4、Cheuk HoHong Ting Hung Hoi Ming RaymondREGISTERED OFFICEP.O.Box 31119Grand PavilionHibiscus Way802 West Bay RoadGrand Cayman KY11205Cayman IslandsHEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG13/F.,Admiralty Centre,Tower 218 Harcourt RoadAdmiraltyHong KongAUDITORZHONGHUI ANDA CPA LimitedCe

5、rtified Public Accountants23rd Floor,Tower 2Enterprise Square Five38 Wang Chiu RoadKowloon BayKowloonSHARE REGISTRAR IN HONG KONGUnion Registrars LimitedRoom 330104,33/FTwo Chinachem Exchange Square338 Kings RoadNorth PointHong KongPRINCIPAL BANKERHang Seng Bank LimitedSTOCK CODE660COMPANY WEBSITEht

6、tp:/www.0660.hkInterim Report 2022/233MANAGEMENT DISCUSSION AND ANALYSISFINANCIAL REVIEWFinancial PerformanceFor the six months ended 31 December 2022,Wai Chun Bio-Technology Limited(the“Company”)and its subsidiaries(collectively,the“Group”)recorded a revenue of approximately HK$405,080,000(six mont